Inhaled cannabis has gained popularity and legal status in many parts of the United States, yet its cardiovascular effects remain unclear. This study, published in the Journal of the American College of Cardiology, aimed to evaluate the acute effects of cannabis inhalation on cardiac ectopy, physical activity, sleep, and glucose levels.
What this study does not show
While the study found a reduction in cardiac ectopy associated with cannabis inhalation, it does not establish a causal relationship or provide insights into long-term effects or mechanisms.
Evidence scorecard
- Analytic validity: established
- Clinical validity: established
- Clinical utility: partial
The evidence class is human_rct, indicating that the findings are based on a randomized controlled trial involving human participants.
The study involved 108 participants, all habitual users of cannabis without a history of cardiac arrhythmias. Participants were randomly assigned to inhale cannabis or abstain for 14 days, with adherence monitored through various methods including surveys and wearable technology.
The primary outcome measured was daily cardiac ectopy, specifically premature atrial contractions (PACs) and premature ventricular contractions (PVCs). Results showed a statistically significant 9% reduction in ectopic beats when participants inhaled cannabis, with a notable 10% decrease in PACs. However, no significant changes were observed in step counts, sleep duration, or glucose levels.
These findings suggest that inhaled cannabis may have a beneficial effect on reducing certain types of cardiac ectopy among habitual users. However, the study’s limitations include imperfect adherence to randomization and potential withdrawal effects, which complicate the interpretation of the results.
Overall, while the study provides valuable insights into the acute effects of cannabis inhalation on cardiac health, further research is necessary to explore the long-term implications and underlying mechanisms.